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While the production of tumor necrosis factor (TNF) and interleukin-6 (IL-6) in septic 
shock and other inflammatory states is well established, the role of interleukin-8 (n-8), a 
recently described neutrophil chemoattractant and activator, has yet to be fully elucidated. Using 
lipopolysaccharide (LPS)-stimulated human whole blood as an ex viva model of sepsis, the 
kinetics of messenger RNA (mRNA) up-regulation and protein release of these cytokines were 
examined. Two waves of cytokine gene activation were documented. TNF and IL-6 were 
induced in the first wave with mRNA levels peaking between 2-4 hours and then rapidly 
declining. TNF and IL-6 protein peaked at 4-6 hours and then stabilized. IL-8 mRNA and 
protein were induced in the first wave, reached a plateau between 6-12 hours, and rose again in a 
second wave which continued to escalate until the end of the 24 hour study. These data 
demonstrate the complex patterns of cytokine gene expression and suggest that production of 
early mediators may augment continued expression of IL-8 to recruit and retain neutrophils at a 
site of inflammation. 0 1991 Academic FJre.55, Inc. 
The morbidity and mortality associated with septic shock are primarily attributable to the 
endogenous mediators released during the host’s response to bacterial LPS (1). One such 
mediator is TNF, a cytokine released primarily by monocytes and tissue macrophages. TNF is 
produced in a rapid burst in response to LPS (2), causing direct functional alterations in a wide 
variety of cell types, as well as inducing the elaboration of a cascade of additional mediators (1). 
Interleukin-6 (IL-6) is another multifunctional cytokine that is released by myeloid cells and by 
other cell types such as fibroblasts and endothelial cells (3). Although the full range of activities 
mediated by IL-6 is as yet unclear, it is also released relatively early in the immune/inflam- 
matory response and may be beneficial to the host by stimulating lymphocyte differentiation, B 
cell proliferation, and the production of immunoglobin and hepatic acute phase proteins. Of 
potential relevance to the pathophysiology of septic shock or local recruitment of neutrophils is a 
recently characterized protein, termed IL-8, that functions as a neutrophil chemoattractnnt and 
activator (4). Originally isolated from the supernatants of LPS-stimulated monocytes (S), this 
cytokine is now known to be produced by a variety of cell types, including endothelial cells, 
fibroblasts, hepatocytes, and keratinocytes (4,6), in response to several inflammatory stimuli, 
including LPS, TNF, and interleukin-1 (IL-l), but not IL-6 (6). 
0006-291X/91 $1.50 
Copyright 0 1991 by Academic Press. im-. 
All rights of reproduction in any form reserved. 18 
Vol. 174, No. 1, 1991 BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS 
Studies detailing the role of TNF and IL-6 in vivo have been conducted in experimental 
animals, but investigations documenting the production of IL-8 have been hampered because the 
exact homolog in rodents is not known. While routine in vitro cell culture methods have 
provided some insights into the regulation of IL-8, an alternative approach involves the use of 
human whole blood (7-9). The ex vivo stimulation of blood with LPS provides a much needed 
bridge between the in vitro experiments with isolated, cultured cells, and studies with human 
patients or primates. Use of the whole blood model reduces the confounding factors that may be 
associated with the isolation of monocytes, such as the adherence-induced expression of cell- 
surface TNF (7) or TNF mRNA (10). Moreover, whole blood represents a more physiologic 
environment for examining cytokine production in response to LPS, since the cellular 
interactions are preserved and the presence of the LPS-binding protein is maintained (11). 
In the present study we sought to carefully dissect the kinetics of cytokine expression 
(both mRNA and protein) in human whole blood in response to LPS. Two distinct waves of 
cytokine gene activation were apparent, with TNF, IL-6 and lL-8 being produced in an early 
wave, and IL-8 being produced in a prolonged second wave. 
MATERIALS AND METHODS 
ExDerimental Design. Blood from normal male volunteers was drawn into heparinized syringes 
(20 U heparin/ml) and placed in sterile 15 ml polypropylene tubes. For each blood sample, a 
total white blood cell count was obtained using a Coulter counter (Coulter Electronics, Hialeah, 
FL) and a blood smear was made and stained with Diff-Quik (Scientific Products, McGaw Park, 
IL). An aliquot of blood (1 ml) was removed from each sample and rapidly processed as 
described below to serve as the 0 hr time point. The remainder of each blood sample 
(approximately 10 ml) was adjusted to 10 pg/ml LPS (Escherichia coli 011 l:B4, Sigma 
Chemical Co., St. Louis, MO) using a 200 pg/ml LPS stock solution. The blood was then placed 
on a rotator in a 37’C CO2 incubator. Control blood samples without added LPS were also 
incubated. A 1 ml aliquot of blood was removed from each sample at several time points and 
processed immediately. Each aliquot was centrifuged at 600 x g for 5 min, the plasma removed, 
diluted 15 with RPM1 1640 media (Whitaker Bioproducts, Walkersville, MD) containing 1% 
fetal calf serum, and stored at -2OOC for later analysis. The buffy coat was then removed from 
the top of the packed red blood celIs and the contaminating red cells were lysed with 0.82% 
NH4Cl. The leukocytes were pelleted by centrifugation at 2000 x g for 5 mitt, dissolved in 0.3 
ml of an RNA extraction buffer (25 mM Tris, pH 8.0, 4.2 M guanidine isothiocyanate, 0.5% N- 
laurosarcosine, and 0.1 M 2-mercaptoethanol), and stored at -2OOC. 
Bioassavs and ELISA, Plasma TNF levels were measured as previously described (12,13) 
using the WEHI 164 subclone 13 cell line, the gift of Dr. Anders Waage, University of 
Trondheim, Norway. The B-9 cell line (the gift of Dr. Jack Gauldie, McMaster University, 
Hamilton, Ontario) was used to assess IL-6 concentrations (14). The plasma IL-8 concentrations 
were determined using a recently-developed ELISA (15) capable of detecting < 100 pg/ml IL-8. 
The assay was performed similarly to a previously described ELISA for TNF developed in our 
laboratory (16). Other cytokines (recombinant human [rh] TNF, rh IL-6, rh IL-1 p) and other 
proteins in the same gene family (connective tissue activating peptide III, platelet factor 4, 
neutrophil activating peptide 2, and gro/melanoma growth stimulating activity [kindly provided 
by Dr. Andreas Huber with the permission of Dr. Alfred Walz]) were tested in this assay and 
found not to cross-react. The number of monocytes (MO)/ml was calculated for each blood 
donor from the tgtal and differential white cell counts. The cytokine assays were normalized to 
represent 1 x 10 MO and results from the 10 donors expressed as mean + SEM. 
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No t em Blot Analvsis. Messenger RNA levels were assessed by Northern blot analysis using 
$J);yy sly described techniques and oligonucleotide probes (17). The blots were hybridized 
P-5’ end-labeled 42 mer oligonucleotide for p-actin (16). After autoradiograms were 
obtained, the blots were sequentially stripped (by heatin 
%?I hr), reprobed, and autoradiographed using the following 
t 80°C in a 1% glycerol solution for 1 
P-5’ end-labeled probes: IL-8 30 mer 
(18); IL-6 30 mer 5’-GGT-GAG-TGG-CTG-TCT-GTG-TGG-GGC-GGC-TAC-3’ (19); and 
TNF 25 mer (16). Autoradiograms were scanned with a laser densitometer (LKB Ultroscan XL). 
The results were normalized to represent equivalent RNA loading in each lane based on the 
intensity of the actin bands, and the intensity of each lane was then expressed as a percentage of 
the band of maximal intensity on each blot. The results for all 10 blots were subsequently 
compiled, expressed as mean + SEM. 
RESULTS 
Consistent with its purported role as a proximal mediator in septic shock (1,2), the 
induction of TNF mRNA was very rapid, reaching 56% of maximum at 1 hour post-LPS 
challenge and peaking between 2 and 4 hour (Fig. 1A). TNF mRNA levels essentially returned 
to baseline, unstimulated levels by 8 hours. Lagging slightly behind the mRNA expression, the 
plasma TNF concentrations increased in a linear fashion to reach a peak at the 4 hour time point 
(558.3 + 60.6 ng/ml/106 monocytes [MO]). Over the remaining time interval, the plasma TNF 
slowly decreased to a level of 353.7 + 49.2 ng/ml/106 MO at the 24 hour time point. The plasma 
TNF concentrations (not corrected to represent 1 x lo6 MO/ml) are shown in Table 1. Samples 
from the 4, 6, and 8 hour time points were run in the WEHI assay in the presence of a rabbit 
polyclonal anti-TNF antibody. Under these conditions, the cytotoxicity of the samples was 
completely neutralized, thus verifying that the measured activity was in fact due to TNF alone 
(data not shown). 
Relative to TNF, IL-6 gene expression and bioactivity were delayed by l-2 hours (Fig. 
1B). After the 1 hour time point, IL-6 mRNA levels showed rapid kinetics of induction, 
reaching a peak at 4 hours and returning to control levels at 8 hours. Maximal IL-6 bioactivity 
lagged behind both the peak TNF bioactivity and the peak IL-6 mRNA by 2 hours. Increasing 
sharply after the 2 hour time point, IL-6 levels reached a plateau at 6 hours (5.5 F I .7 t&ml/106 
MO). Uncorrected IL-6 levels are shown in Table 1. 
IL-8 gene expression and protein release, in contrast, showed a markedly different pattern 
of regulation (Fig. 1C). IL-8 mRNA levels increased to approximately 30% of the maximum 
over the first 4 hours and then remained at this level until the 12 hour time point. Subsequently, 
the mRNA levels increased rapidly, reaching a maximum at 24 hours. The appearance of IL-8 in 
the plasma followed a similar time course. After lagging behind mRNA expression during the 
initial 4 hours, the IL-8 levels reached a plateau of approximately 20 ng/ml/106 MO at the 8 and 
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Figure 1. Kinetics of TNF, IL-6, and IL-8 mRNA expression and protein release in LPS- 
stimulated human whole blood. Blood from normal male volunteers (n = 10) was stimulated 
with 10 pg/ml LPS. At the indicated time poin 
R-8. The values were adjusted to reflect 1 x 6”. 
the plasma was analyzed for TNF, IL-6, and 
10 monocytes (MO), and are expressed as mean 2 
SEM. Total RNA was extracted from the leukocytes and subjected to Northern blot analysis. 
The autoradiograms were scanned by laser densitometry, and the results were normalized to 
represent equivalent RNA loading based on the intensity of the actin bands. The compiled 
results are expressed as % maximum intensity + SEM. 
12 hour time points and thereafter increased very rapidly. The IL-8 concentration at the 24 hour 
time point was 64.8 + 13.0 ng/ml/106 MO, and, consistent with the IL-8 mRNA profile, did not 
appear to be reaching a plateau (see Table 1 for uncorrected IL-8 concentrations). 
The dramatic differences in the kinetics of cytokine mRNA are readily evident in 
autoradiograms of a single representative blot sequentially probed for TNF, IL-6, IL-8, and p- 
actin (Fig. 2). TNF and IL-6 mRNA were under tight regulation as suggested by the rapid 
kinetics of their induction and disappearance. The levels of IL-8 mRNA, however, continued to 
increase throughout the entire time course. 
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Table 1. Measured TNF, IL-6 and IL-8 levels, uncorrected for the number of monocytes/ml 
Incubation 7-m hzhl) 
Time Mean + SD 
ON (Range) 
IL-6 (&ml) 
Mean + SD 
(Range) 
IL-8 (@ml) 
Mean + SD 
(Raw) 
4 230.3 + 90.2 0.6 + 0.4 4.Ok3.1 
(1005383.3) (0.1-1.4) (1.4-11.9) 
6 225.6 + 88.4 2.5 + 2.6 6.3 4.0 + 
(99.6-438.0) (0.4-9.8) (3.3-15.8) 
24 139.0 + 45.6 3.8 f. 3.2 26.3 19.9 + 
(74.6-224.2) (0.5-12.7) (11.0-81.0) 
Whole blood from normal male donors (n=lO) was stimulated with 10 l.tg/ml LPS and plasma 
TNF, IL-6 and IL-8 concentrations were measured. The time points resulting in maximal TNF, 
IL-6, and IL-8 concentrations are shown. 
A control study was performed to examine cytokine release from whole blood incubated 
under identical conditions but in the absence of added LPS. Very low concentrations of these 
cytokines were detected. Between 3 and 24 hours of incubation, the average release of TNF, IL- 
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Autoradiograms of a representative Northern blot sequentially probed for TNF, IL-6, Figure 2. 
IL-8, and p-actin. Whole blood was stimulated with 10 pg/ml LPS. Total leukocyte RNA was 
extracted at the indicated time points and subjected to Northern blot analysis. 
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release measured in the presence of LPS. In addition, this kinetics study has been repeated, and. 
while the relative concentrations of the cytokines has been found to vary somewhat, the patterns 
of release were very consistent. 
DISCUSSION 
This ex viva model of sepsis provides a window to observe the kinetics of human 
cytokine production after LPS stimulation. Relative to one another, the peak in TNF levels (4 
hour time point) was found to precede the maximal IL-6 levels (6 hour time point) by 
approximately 2 hours. This is in agreement with what has been observed both in clinical and 
experimental studies (20,21), and may be explained by the ability of TNF, in addition to LPS, to 
induce IL-6 production (21). In contrast, IL-8 demonstrated a completely different profile of 
gene expression and protein secretion. These results are consistent with the prolonged 
expression of IL-8 mRNA and protein which has been observed in isolated monocytes, 
endothelial cells, and keratinocytes in response to stimuli including LPS, TNF, IL-l, and 
gamma-interferon (18, 22,23). 
These marked differences in the kinetics of cytokine production undoubtedly provide a 
reflection of the functional differences of these mediators. TNF has been characterized as a 
proximal mediator of the response to LPS, with its rapid production inducing regulatory changes 
in a wide variety of cell types as well as initiating the release of a cascade of other mediators 
(1,4). The role of n-6 in sepsis is less clear, but appears to constitute a signal which stimulates 
lymphocyte growth and differentiation and induces the production of antibody and hepatic acute 
phase proteins. IL-8, in contrast, possesses a very different spectrum of functions. It has been 
characterized as a neutrophil chemoattractant and activator and has more recently been found to 
possess the apparently anti-inflammatory function of preventing the adhesion of neutrophils to 
endothelium (24). The unusual profile of IL-8 release, with the n-8 mRNA levels and protein 
reaching a plateau between 4 and 12 hours and then rising, may reflect these diverse functions, 
or alternatively may represent a response to multiple stimuli for IL-8 release. LPS and TNF both 
elicit IL-8 production from monocytes, suggesting that the second wave of IL-8 production may 
be induced by the earlier wave of TNF. Studies are underway to investigate this possibility. 
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